Read the blog related to this supplement.
Volume 14 Supplement 6
Viral Hepatitis and Drug Use in Europe
Research and Commentaries
Edited by Jeffrey V Lazarus and Kevin A Fenton
This publication has been produced with the financial support of the Drug Prevention and Information Programme (DPIP) of the European Union. The contents of this publication are the sole responsibility of the authors and can in no way be taken to reflect the view of the European Commission. The publication charges for this supplement were funded by AbbVie as an unresitricted grant to Rigshospitalet, the University of Copenhagen, Denmark. AbbVie further co-funded the printing of the supplement. The peer review process was overseen by the Supplement Editors in accordance with BioMed Central's peer review guidelines for supplements. The Supplement Editors declare that they have no competing interests.
-
Citation: BMC Infectious Diseases 2014 14(Suppl 6):S1
-
No strategy to meet the HCV epidemic
Citation: BMC Infectious Diseases 2014 14(Suppl 6):S2 -
Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe
Citation: BMC Infectious Diseases 2014 14(Suppl 6):S3 -
Ending the mass criminalisation of people who use drugs: a necessary component of the public health response to hepatitis C
Citation: BMC Infectious Diseases 2014 14(Suppl 6):S4 -
A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients
Citation: BMC Infectious Diseases 2014 14(Suppl 6):S5 -
A national multidisciplinary healthcare network for treatment of hepatitis C in people who inject drugs in Slovenia
Citation: BMC Infectious Diseases 2014 14(Suppl 6):S6 -
The successful implementation of Scotland’s Hepatitis C Action Plan: what can other European stakeholders learn from the experience? A Scottish voluntary sector perspective
Citation: BMC Infectious Diseases 2014 14(Suppl 6):S7 -
Improving the quality of needle and syringe programmes: an overlooked strategy for preventing hepatitis C among people who inject drugs
Citation: BMC Infectious Diseases 2014 14(Suppl 6):S8 -
Consensus for the integrated management of hepatitis C in Portugal
Citation: BMC Infectious Diseases 2014 14(Suppl 6):S9 -
A perspective from drug user organisations on ‘ECDC and EMCDDA guidance: prevention and control of infectious diseases among people who inject drugs’
Citation: BMC Infectious Diseases 2014 14(Suppl 6):S10 -
A policy-maker’s perspective on ‘ECDC and EMCDDA guidance: prevention and control of infectious diseases among people who inject drugs’
Citation: BMC Infectious Diseases 2014 14(Suppl 6):S11 -
Hepatitis C virus seroprevalence among people who inject drugs and factors associated with infection in eight Russian cities
Behavioural surveillance among people who inject drugs (PWID) and testing for hepatitis C virus (HCV) and HIV is needed to understand the scope of both epidemics in at-risk populations and to suggest steps to ...
Citation: BMC Infectious Diseases 2014 14(Suppl 6):S12 -
HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective
Citation: BMC Infectious Diseases 2014 14(Suppl 6):S13 -
Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries
Hepatitis C virus (HCV) infection represents a major global health problem, which in high-income countries now mostly affects people who inject drugs (PWID). Many studies show that the treatment of HCV infecti...
Citation: BMC Infectious Diseases 2014 14(Suppl 6):S14 -
Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey
Unsafe injections, through infectious bodily fluids, are a major route of transmission for hepatitis B and C. Viral hepatitis burden among people who inject drugs is particularly high in many Member States of ...
Citation: BMC Infectious Diseases 2014 14(Suppl 6):S15 -
A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region
Fifteen million adults in the World Health Organization European Region are estimated to have active hepatitis C infection. Intravenous drug use is a major hepatitis C transmission route in this region, and pe...
Citation: BMC Infectious Diseases 2014 14(Suppl 6):S16 -
Hepatitis C in European prisons: a call for an evidence-informed response
Globally, over 10 million people are held in prisons and other places of detention at any given time. People who inject drugs (PWID) comprise 10-48% of male and 30-60% of female prisoners. The spread of hepati...
Citation: BMC Infectious Diseases 2014 14(Suppl 6):S17 -
Roundtable discussion: how lessons learned from HIV can inform the global response to viral hepatitis
Citation: BMC Infectious Diseases 2014 14(Suppl 6):S18
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 3.4
5-year Journal Impact Factor: 3.3
Source Normalized Impact per Paper (SNIP): 1.106
SCImago Journal Rank (SJR): 1.031
Speed 2023
Submission to first editorial decision (median days): 13
Submission to acceptance (median days): 148
Usage 2023
Downloads: 6,949,317
Altmetric mentions: 28,444
Peer-review Terminology
-
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication